Literature DB >> 2570338

Involvement of platelet-activating factor (PAF) in endotoxin-induced intestinal motor disturbances in rats.

L Pons1, M T Droy-Lefaix, P Braquet, L Buéno.   

Abstract

Intestinal myoelectrical activity was investigated in conscious fasted rats chronically implanted with Nichrome electrodes in the duodeno-jejunum. Motility of the small intestine was characterized by the presence of migrating myoelectric complex (MMC) occurring regularly at 16.2 +/- 5.8 minute intervals. Intravenous administration of endotoxin (E. coli S.0111:B4) at a dose of 50 micrograms/kg increased the interval between MMC to 112.6 +/- 26.8 min, the duration of these effects being dose-related between 10 to 100 micrograms/kg. Such a typical myoelectrical alteration, corresponding to rapidly propagated groups of spike bursts, was mimicked by the IP administration of PAF at doses of 10 to 50 micrograms/kg. Previous administration of BN 52021, a specific PAF antagonist at a dose of 50 mg/kg abolished the motor alterations induced by IP injection of PAF (25 micrograms/kg) and significantly (p less than 0.01) reduced by 61.2% those induced by IV endotoxin (50 micrograms/kg). Indomethacin (10 mg/kg IP) as well as SC 19220 (5 mg/kg IV), a PGE2 antagonist, injected prior to endotoxin (50 micrograms/kg IV) or PAF (25 micrograms/kg IP) also reduced significantly (p less than 0.01) the duration of MMC inhibition. It is concluded that endogenous release of PAF is partly responsible for the intestinal motor alterations induced by endotoxin; these effects, strongly reduced after treatment with BN 52021, are also mediated through the release of prostaglandins.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2570338     DOI: 10.1016/0024-3205(89)90104-5

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  7 in total

Review 1.  PAF. A review of its effects, antagonists and possible future clinical implications (Part II).

Authors:  M Koltai; D Hosford; P Guinot; A Esanu; P Braquet
Journal:  Drugs       Date:  1991-08       Impact factor: 9.546

2.  Possible involvement of adrenomedullin in lipopolysaccharide-induced small-intestinal motility changes in conscious rats.

Authors:  Sarwar Hussain; Reiko Miyazawa; Takeshi Tomomasa; Hiroaki Kaneko; Atsushi Takahashi; Toshio Watanabe; Hirokazu Arakawa; Akihiro Morikawa
Journal:  J Gastroenterol       Date:  2005-12       Impact factor: 7.527

3.  Role of central interleukin-1 beta in gastrointestinal motor disturbances induced by lipopolysaccharide in sheep.

Authors:  M A Plaza; J Fioramonti; L Bueno
Journal:  Dig Dis Sci       Date:  1997-02       Impact factor: 3.199

4.  Quinidine, but not eicosanoid antagonists or dexamethasone, protect the gut from platelet activating factor-induced vasoconstriction, edema and paralysis.

Authors:  Ingmar Lautenschläger; Inéz Frerichs; Heike Dombrowsky; Jürgen Sarau; Torsten Goldmann; Karina Zitta; Martin Albrecht; Norbert Weiler; Stefan Uhlig
Journal:  PLoS One       Date:  2015-03-20       Impact factor: 3.240

5.  Signalling mechanisms in PAF-induced intestinal failure.

Authors:  Ingmar Lautenschläger; Yuk Lung Wong; Jürgen Sarau; Torsten Goldmann; Karina Zitta; Martin Albrecht; Inéz Frerichs; Norbert Weiler; Stefan Uhlig
Journal:  Sci Rep       Date:  2017-10-17       Impact factor: 4.379

6.  Platelet-activating factor mediates trinitrobenzene induced dysmotility in the left colon.

Authors:  W E Longo; J Standeven; B Chandel; Y Deshpande; A M Vernava; D Kaminski
Journal:  Mediators Inflamm       Date:  1995       Impact factor: 4.711

Review 7.  Gastrointestinal motility and disease in large animals.

Authors:  C B Navarre; A J Roussel
Journal:  J Vet Intern Med       Date:  1996 Mar-Apr       Impact factor: 3.333

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.